Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for BioScience Health Innovations's EV-to-FCF or its related term are showing as below:
BHIC'
s EV-to-FCF Range Over the Past 10 Years
Min: -5200.61 Med: -47.44 Max: 33303.24
Current: -62.46
During the past 7 years, the highest EV-to-FCF of BioScience Health Innovations was 33303.24. The lowest was -5200.61. And the median was -47.44.
BHIC's EV-to-FCF is ranked worse than 100% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 18.06
vs BHIC: -62.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioScience Health Innovations (OTCPK:BHIC) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioScience Health Innovations's PE Ratio (TTM) for today is calculated as:
BioScience Health Innovations's share price for today is $4.081.
BioScience Health Innovations's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioScience Health Innovations EV-to-FCF Related Terms
BioScience Health Innovations EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's EV-to-FCF falls into.
BioScience Health Innovations's current Enterprise Value is $45.91 Mil.
BioScience Health Innovations's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations (BHIC) has a EV-to-FCF of -62.46 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioScience Health Innovations and its competitors. According to the industry distribution chart, BioScience Health Innovations ranks #999999 out of 405 companies in the Healthcare Providers & Services industry.
Is BioScience Health Innovations' EV-to-FCF too high?
BioScience Health Innovations' current EV-to-FCF is -62.46. Based on the distribution chart, BioScience Health Innovations ranks #999999 out of 405 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' EV-to-FCF compare to SHFH and PETS?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #999999 out of 405 companies for EV-to-FCF. This places BioScience Health Innovations in the lower half of its industry. The industry median EV-to-FCF is 18.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.06, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current EV-to-FCF is -62.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.08 — trading 97.5% below its estimated fair value. The current EV-to-FCF is -62.46. BioScience Health Innovations' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current EV-to-FCF is -62.46 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.08 is trading 97.5% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
EV-to-FCF: -62.46
GF Value™: $164.84 vs. price of $4.08 (97.5% below fair value)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
49GF Score
Get the complete analysis for BHIC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
